Jay053
20 Nov 2018
Rise - 8.4p target Agm today. Results due and contract expiry so expecting renewal rns. Twitter ramping TA and 8.4 target.
dickie3times
05 Jun 2018
Rumours...Jap/German Pharmas Rumours circulating where i work (bio-chem company) two Japanese pharmas and a German Pharma are on a shopping spree and are interested in cancer drug and ED/Sildenafil drugs reformulation, no other info except they'll be making themselves known soon but i will emphasise, i do not know if it involves PYC...I'm trying to find out more...but lips are firmly sealed
inforapoundtoo
21 May 2018
Re: PYC will be big - part 2 At a price of 6.15p, the company is valued at a lowly £3.6mln, but Millen points out that is five times more than a year ago.Millen SHOULD also point out...…………...but many, many, many times LOWER than historic values
dickie3times
17 May 2018
Re: PYC will be big - part 2 Personalised MedicineInnovate UK’s grants were for studies in personalised medicine, which involves treating individuals or groups in a specific way rather than a one-size fits all approach.[link] typically prescribe medicine irrespective of who you are, your genetic make up, your age and what other conditions you might have had.“Personalised treatments take these into account and give a treatment optimised to give the best outcome for an individual.“Virtual Tumour can help predict the effect of cancer drugs on subsets of patients, which makes it very well positioned to help develop personalised treatments.”Millen admits the work with Innovate has more of a ‘blue sky’ element than its standard core service but he believes there is a lot of future potential.Revenues on the riseIn the meantime, the contracts already won this year should this year produce a significant jump in revenues.Turnover in the year to June 2017 was £270,000 with a net loss of £400,000 but some of the €500,000 from Merck will fall into this calendar year in addition to the £153,000 from the three new contracts plus the £68,00 Innovate grant.At a price of 6.15p, the company is valued at a lowly £3.6mln, but Millen points out that is five times more than a year ago.“Momentum is building and we are establishing a history of delivering what we say.”[link]
dickie3times
17 May 2018
PYC will be big Physiomics PLC: Personalised medicines will build on momentum from recent pharma dealsTo clarify, this is not the US pharma supermajor Merck but an unrelated German firm also known as Merck Serono.This Merck though still has 50,000 staff, a net worth in the billions and is also a cancer drug developer so it’s not hard to spot why investors were so enthusiastic.[link] Serono a big nameNot only does the deal generate a significant amount of revenue, but interestingly Merck Serono also allowed its name to be linked with the contract.In the secretive world of pharma/biotech drug development that is unusual says Jim Millen, Physiomics’ chief executive, who sees it as a clear validation of the progress made by the company since he took charge two years ago.The German company had been working with Physiomics for some time but the contract was a significant step-up in scale and might herald further even deals not only with Merck Serono but other pharmas.Cancer simulation technologyAs the name implies, Virtual Tumour is a simulation programme. The software predicts the effect of different combinations of drugs on whatever type of cancer a pharma might be researching.Millen says Virtual Tumour helps the pharma decide the optimum combinations of drugs for a specific cancer along with other important elements such as dose sizes and how it should be administered.It gives a head start when designing development programmes and helps to avoid costly failures especially in clinical trials.As new cancer drugs can cost up to US$1bn, involve 10 years of work and still fail right at the end of the process, anything a pharma can do to increase the probability of success is worth something, he says.VT very adaptableSo far, Virtual Tumour has been used to model 40-50 types of the disease but its adaptability means it has the potential to be used across all areas of oncology, says Millen. Since the Merck KgaA deal, Physiomics has also picked up contracts from two more major pharma groups and a smaller UK biotech, though none of these have been named.A second grant has also been made to the company from the government-backed tech innovation body Innovate UK.The first grant was for £131,000 while a further £68,000 was recently awarded as part of a programme researching prostate cancer chemotherapy dosing.Millen says Physiomics’ sweet spot is in pre-clinical in vivo work (animals primarily) and phase I and II early stage clinical trials.Depending on their size, early-stage clinical trials can cost £1mln for a phase 1 and up to £15mln for a phase II.Phase III trials can cost hundreds of millions, so it important the pharma companies gets it right in the early stages says Millen.Personalised MedicineInnovate UK’s grants were for studies in personalised medicine, which involves treating individuals or groups in a specific way rather than a one-size fits all approach.“Doctors typically prescribe medicine irrespective of who you are, your genetic make up, your age and what other conditions you might have had.“Personalised treatments take these into account and give a treatment optimised to give the best outcome for an individual.“Virtual Tumour can help predict the effect of cancer drugs on subsets of patients, which makes it very well positioned to help develop personalised treatments.”Millen admits the work with Innovate has more of a ‘blue sky’ element than its standard core service but he believes there is a lot of future potential.Revenues on the riseIn the meantime, the contracts already won this year should this year produce a significant jump in revenues.Turnover in the year to June 2017 was £270,000 with a net loss of £400,000 but some of the €500,000 from Merck will fall into this calendar yea
dickie3times
25 Apr 2018
Major shareholders [link] shares are not traded on any other exchanges and there is no restriction on the transfer of shares. The total number of ordinary shares in issue is: 58,785,394.Not in public hands: 69.13% of which 66.82% are held in nominee accounts.Significant Shareholders (as at 3rd January 2018)Investor Name Holding Interactive Investor Service 22.4% Hargreaves Lansdown (Nominees) 16.8% HSDL Nominees Limited 14.8% Barclays Direct Investing Nominees 12.7% Vidacos Nominees 5.4% HSBC Client Holdings Nominee (UK) 3.4%
dickie3times
25 Apr 2018
More deals 'imminent' BIG Pharma is imo, showing interest in doing a farm in deal with PYC. My guess it will be MERCK....They like VT and again, imo, they want it.
alltold9
23 Apr 2018
Re: STAKEBUILDING! Phase 2 towards £2+ imhho. Massive news could break anytime?
dickie3times
19 Apr 2018
VT and grants "This grant project, focused on the personalisation of oesophageal cancer treatment, has driven insights that may be integrated into our core Virtual Tumour offering and will also be the subject of thought capital that will be exploited over the course of this calendar year at industry conferences and through the publication of scientific papers in order to garner further interest from the drug research community. Finally, the ideas generated by this project have the potential to be taken forward in a further personalised medicine project for which the Company is currently seeking funding."Having presented 'successfully' last week at the AACR conference in Chicago,US, this coming week they will present on Tuesday 24th April 2018 at BioTrinity in the UK (Europe's leading Investment and Partnering conference for the BioPharma industry). Following that their previous funding partners the Government Innovate UK body will be launching a Personalised Medicine investment accelerator looking to invest £0.5m-1.5m in projects run by SMEs. [link] clearly a £3m company like Physiomics winning a big funding contract like that would be both an immense validation of their technology and approach but also fund their in a NON-DILUTIVE manner for many years.It's interesting that the UK Government is funding SMEs to tackle the Holy Grail of Personalised Medicine but there are other massive AI companies involved who could I suggest partner with Physiomics. Imagine £3m Physiomics announcing a deal with Jeff Bezos' $1bn+ cancer detection/personalised medicine start-up/roll-up Grail or how about with Google's UK AI specialist DeepMind (which they bought for $500m) and has an operation called DeepMind Health looking to work with Academics and the NHS for cancer detection/personalised medicine. This is something the market has not considered as of yet because they still see PYC as simply being a Company that will have biotechs and Pharmas as potential customers.[link] Inc., a precision medicine and life sciences company aiming to develop new very early detection techniques for cancer, has attracted more than $900 million in investment capital from some of the most well-known names in pharmaceutical sales and development.Bristol-Myers Squibb, Celgene, Merck, and Johnson & Johnson Innovations have joined with other strategic investors, including Amazon’s Jeff Bezos and McKesson Ventures, to contribute hundreds of millions to the company’s financial future.“We envision a global community that benefits from early-stage cancer detection where fewer individuals face the anguish of late-stage diagnosis and devastating outcomes,” said Jeff Huber, GRAIL’s Chief Executive Officer.“I believe that GRAIL’s approach leveraging high-intensity sequencing, population-scale clinical studies, and state of the art computer science and data science is unparalleled in the field of cancer detection."
clockwurktangerine
04 Feb 2018
N4P Has a proper alliance.Pyc never will....
clockwurktangerine
27 Jan 2018
Not publicly quoted! "Brunel Institutes Bioengineering Division's modelling system can simulate tumour growth from a few cancer cells to a mature solid tumour..."Funded by private equity and gov funding..If successful an IPO would be considered.As opposed to listed Pyc where CEO type salaries have to be maintained!
dickie3times
26 Jan 2018
Re: News will come..... AND IT CAME......so down we go. This deal is only worth 35k but that is only the beginning. The so called Major is unnamed for a reason, it is a big BIG company and will be given the chance to prove for themselves VT its effects and efficacy. IF they are satisfied then multi-million pound deals could be the next step....it's a start, so investors should not underestimate this deal. Brilliant, imo
clockwurktangerine
25 Jan 2018
Re: STAKEBUILDING! What JC! The insipid vapour king!No interest at all in Pyc other then to buy, see the buye4s appear, so increase then sell as he has done!He did not buy on knowing an RNs was on its way, has no interest other then having money to burn and personal gain!Qed
alltold9
24 Jan 2018
STAKEBUILDING! Happy days ahead!
dickie3times
10 Jan 2018
News will come..... .....and when it does all the uncertainties will be in the past. I believe very soon the sp will turn around big time as pi's and traders get ready for some fireworks from Merck.Traders have had their month of fun....it's LTH's turn now.....and mine too, yes this is one of my hidden stocks, stored somewhere where i forget i'm actually holding....just dug it out, lol[link]
